Recent News

• 11.04.2026 - BioCryst to Present at Upcoming Investor Conferences
• 11.04.2026 - BioCryst Reports Third Quarter 2026 Financial Results
• 10.29.2026 - BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
• 10.21.2026 - BioCryst to Report Third Quarter 2026 Financial Results on November 4
• 10.21.2026 - BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
• 10.05.2026 - BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
• 09.01.2026 - BioCryst to Present at Upcoming Investor Conference
• 08.25.2026 - BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
• 08.05.2026 - BioCryst Reports Second Quarter 2026 Financial Results
• 07.22.2026 - BioCryst to Report Second Quarter 2026 Financial Results on August 5

Recent Filings

• 11.04.2026 - EX-99.1 EX-99.1
• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors